Most-cited articles · 2019

The 50 most-cited articles in Value in Health, 2019

Ranked by OpenAlex citation count on 29 October 2026, out of 784 eligible articles Value in Health published in 2019. Ranks are frozen; this page will not change. Number one, with 664 citations: PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains.

Cohort
784 articles
Listed
Top 50 (6.4%)
Open access
50 of 50
Snapshot
2026-10-29

The most-cited Value in Health articles of 2019 cluster around measurement and valuation of health outcomes. Prominent themes include patient-reported outcome measures and their implementation, health state valuation for instruments such as the EQ-5D-5L, and methodological guidance for health economic analysis. The top paper, "PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains" by Cella, Choi, Condon and colleagues, leads with 664 citations, followed by work on United States valuation of EQ-5D-5L health states and an overview of the international EQ-5D-5L valuation protocol.

For readers, the list offers a citation-based view of which 2019 contributions drew the most attention in the field. It spans outcome measurement, preference elicitation, machine learning, risk prediction, and health technology assessment, and can serve as a starting point for locating influential references on these topics.

Introduction written from the titles and abstracts on this list. Every figure below is the source.

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 1
    top 0.2%

    PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains

    David F Cella, Seung Woo Choi, David M. Condon, Ben Schalet, Ron D. Hays and 10 more

    664 citationsOpen accessdoi:10.1016/j.jval.2019.02.004OpenAlex

  2. 2
    top 0.3%

    United States Valuation of EQ-5D-5L Health States Using an International Protocol

    Alan Simon Pickard, Ernest H. Law, Ruixuan Jiang, Eleanor Pullenayegum, James W. Shaw and 7 more

    392 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.02.009OpenAlex

    Show abstract

    OBJECTIVE: To derive a US-based value set for the EQ-5D-5L questionnaire using an international, standardized protocol developed by the EuroQol Group. METHODS: Respondents from the US adult population were quota-sampled on the basis of age, sex, ethnicity, and race. Trained interviewers guided participants in completing composite time trade-off (cTTO) and discrete choice experiment (DCE) tasks using the EuroQol Valuation Technology software and routine quality control measures. Data were modeled using a Tobit model for cTTO data, a mixed logit model for DCE data, and a hybrid model that combined cTTO and DCE data. Model performance was compared on the basis of logical ordering of coefficients, statistical significance, parsimony, and theoretical considerations. RESULTS: Of 1134 respondents, 1062, 1099, and 1102 respondents provided useable cTTO, DCE, and cTTO or DCE responses, respectively, on the basis of quality control criteria and interviewer judgment. Respondent demographic characteristics and health status were similar to the 2015 US Census. The Tobit model was selected as the…

  3. 3
    top 0.4%

    Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol

    Elly A. Stolk, Kristina Ludwig, Kim Rand, Ben van Hout, Juan Manuel Ramos-Goñi

    361 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2018.05.010OpenAlex

    Show abstract

    A standardized 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L) valuation protocol was first used in national studies in the period 2012 to 2013. A set of problems encountered in this initial wave of valuation studies led to the subsequent refinement of the valuation protocol. To clarify lessons learned and how the protocol was updated when moving from version 1.0 to the current version 2.1 and 2.0, this article will (1) present the challenges faced in EQ-5D-5L valuation since 2012 and how these were resolved and (2) describe in depth a set of new challenges that have become central in currently ongoing research on how EQ-5D-5L health states should be valued and modeled.

  4. 4
    top 0.6%

    Adjusting for Inflation and Currency Changes Within Health Economic Studies

    Hugo C. Turner, Jeremy Addison Lauer, Bach Xuan Tran, Yot Teerawattananon, Mark Jit

    342 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.03.021OpenAlex

    Show abstract

    OBJECTIVES: Within health economic studies, it is often necessary to adjust costs obtained from different time periods for inflation. Nevertheless, many studies do not report the methods used for this in sufficient detail. In this article, we outline the principal methods used to adjust for inflation, with a focus on studies relating to healthcare interventions in low- and middle-income countries. We also discuss issues relating to converting local currencies to international dollars and US$ and adjusting cost data collected from other countries or previous studies. METHODS: We outlined the 3 main methods used to adjust for inflation for studies in these settings: exchanging the local currency to US$ or international dollars and then inflating using US inflation rates (method 1); inflating the local currency using local inflation rates and then exchanging to US$ or international dollars (method 2); splitting the costs into tradable and nontradable resources and using method 1 on the tradable resources and method 2 on the nontradable resources (method 3). RESULTS: In a hypothetical…

  5. 5
    top 0.7%

    Machine Learning for Health Services Researchers

    Patrick Doupé, James H. Faghmous, Sanjay Basu

    297 citationsOpen accessdoi:10.1016/j.jval.2019.02.012OpenAlex

  6. 6
    top 0.8%

    Bayesian Networks for Risk Prediction Using Real-World Data: A Tool for Precision Medicine

    Paul Arora, Devon J. Boyne, Justin Slater, Alind Gupta, Darren R. Brenner and 1 more

    193 citationsOpen accessdoi:10.1016/j.jval.2019.01.006OpenAlex

  7. 7
    top 0.9%

    Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

    Rob M.P.M. Baltussen, Kevin Marsh, Praveen Thokala, Vakaramoko Diaby, Héctor Castro and 18 more

    174 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.06.014OpenAlex

    Show abstract

    OBJECTIVE: Recent years have witnessed an increased interest in the use of multicriteria decision analysis (MCDA) to support health technology assessment (HTA) agencies for setting healthcare priorities. However, its implementation to date has been criticized for being "entirely mechanistic," ignoring opportunity costs, and not following best practice guidelines. This article provides guidance on the use of MCDA in this context. METHODS: The present study was based on a systematic review and consensus development. We developed a typology of MCDA studies and good implementation practice. We reviewed 36 studies over the period 1990 to 2018 on their compliance with good practice and developed recommendations. We reached consensus among authors over the course of several review rounds. RESULTS: We identified 3 MCDA study types: qualitative MCDA, quantitative MCDA, and MCDA with decision rules. The types perform differently in terms of quality, consistency, and transparency of recommendations on healthcare priorities. We advise HTA agencies to always include a deliberative component.…

  8. 8
    top 1.1%

    Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report

    John Edward Brazier, Roberta Ara, Ismail Azzabi Zouraq, Jan J.V. Busschbach, Hélène Chevrou‐Séverac and 6 more

    166 citationsOpen accessdoi:10.1016/j.jval.2019.01.004OpenAlex

  9. 9
    top 1.2%

    EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set

    Simone Kreimeier, Wolfgang Greiner

    157 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2018.11.001OpenAlex

    Show abstract

    OBJECTIVES: Interest in the measurement of health-related quality of life (HRQoL) in children and adolescents has been increasing, and appropriate instruments are required for this target group. This article focuses on the EQ-5D-Y instrument, presenting an overview of its characteristics, development, and current use, and includes a discussion of methodological and conceptual issues related to the valuation of child health and the development of an EQ-5D-Y value set. METHODS: This article brings together the experiences of the research team that developed and validated the EQ-5D-Y, supplemented by information derived from EQ-5D-Y study registrations on the EuroQol Group's website. RESULTS: EQ-5D-Y is a child-specific and age-appropriate measure of HRQoL. Study registration data show that the instrument's use has steadily increased since its first publication. It has been used in various types of studies and in different disease areas. Currently there is no value set for EQ-5D-Y, and so its use in cost-utility analysis (CUA) is limited. There are methodological and conceptual issues…

  10. 10
    top 1.3%

    Implementing Patient-Reported Outcome Measures in Clinical Breast Cancer Care: A Systematic Review

    Laurentine S. E. van Egdom, Arvind Oemrawsingh, Lisanne M. Verweij, Hester Floor Lingsma, Linetta B. Koppert and 3 more

    151 citationsOpen accessdoi:10.1016/j.jval.2019.04.1927OpenAlex

  11. 11
    top 1.5%

    Are Healthcare Choices Predictable? The Impact of Discrete Choice Experiment Designs and Models

    Esther Wilhelmina de Bekker-Grob, Joffre Swait́, Habtamu Tilahun Kassahun, Michiel C.J. Bliemer, Marcel F. Jonker and 4 more

    139 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.04.1924OpenAlex

    Show abstract

    BACKGROUND: Lack of evidence about the external validity of discrete choice experiments (DCEs) is one of the barriers that inhibit greater use of DCEs in healthcare decision making. OBJECTIVES: To determine whether the number of alternatives in a DCE choice task should reflect the actual decision context, and how complex the choice model needs to be to be able to predict real-world healthcare choices. METHODS: Six DCEs were used, which varied in (1) medical condition (involving choices for influenza vaccination or colorectal cancer screening) and (2) the number of alternatives per choice task. For each medical condition, 1200 respondents were randomized to one of the DCE formats. The data were analyzed in a systematic way using random-utility-maximization choice processes. RESULTS: Irrespective of the number of alternatives per choice task, the choice for influenza vaccination and colorectal cancer screening was correctly predicted by DCE at an aggregate level, if scale and preference heterogeneity were taken into account. At an individual level, 3 alternatives per choice task and…

  12. 12
    top 1.6%

    A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016)

    Ari Gnanasakthy, Amy M Barrett, Emily Evans, Denise D’Alessio, Carla DeMuro

    129 citationsOpen accessdoi:10.1016/j.jval.2018.09.2842OpenAlex

  13. 13
    top 1.7%

    Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions

    Rick A. Vreman, Inkatuuli Heikkinen, Ad Schuurman, Claudine Sapède, Jordi Llinares and 5 more

    125 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.07.007OpenAlex

    Show abstract

    BACKGROUND: Despite increasing informal and formal use of unmet medical need (UMN) in drug development, regulation, and assessment, there is no insight into its definitions in use. This study aims to provide insight into the current definitions in use and to provide a starting point for a multi-stakeholder discussion on alignment. METHODS: A scoping and a gray literature review were performed to locate definitions of UMN in literature and on stakeholder websites. These definitions were categorized and then discussed among the multi-stakeholder author group via semistructured group discussions and open session workshops with a broader stakeholder audience. Issues with the formation of a common definition and mechanisms for use were discussed. RESULTS: The reviews yielded 16 definitions. Differences were evident, but all included 1 or more of the following elements: (adequacy of) available treatments (16 of 16: 100%), disease severity or burden (6 of 16: 38%), and patient population size (1 of 16: 6%). The stakeholder discussions led to a suggestion for a definition including the…

  14. 14
    top 1.8%
  15. 15
    top 2%

    Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L

    Eliza Lai‐Yi Wong, Annie Wai-Ling Cheung, A Wong, Richard Huan Xu, Juan Manuel Ramos-Goñi and 1 more

    107 citationsOpen accessdoi:10.1016/j.jval.2019.02.014OpenAlex

  16. 16
    top 2.1%
  17. 17
    top 2.2%

    Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies

    Selena Russo, Chiara Jongerius, Flavia Faccio, Silvia Francesca Maria Pizzoli, Cathy Anne Pinto and 9 more

    96 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2018.12.007OpenAlex

    Show abstract

    BACKGROUND: Research has been mainly focused on how to elicit patient preferences, with less attention on why patients form certain preferences. OBJECTIVES: To assess which psychological instruments are currently used and which psychological constructs are known to have an impact on patients' preferences and health-related decisions including the formation of preferences and preference heterogeneity. METHODS: A systematic database search was undertaken to identify relevant studies. From the selected studies, the following information was extracted: study objectives, study population, design, psychological dimensions investigated, and instruments used to measure psychological variables. RESULTS: Thirty-three studies were identified that described the association between a psychological construct, measured using a validated instrument, and patients' preferences or health-related decisions. We identified 33 psychological instruments and 18 constructs, and categorized the instruments into 5 groups, namely, motivational factors, cognitive factors, individual differences, emotion and…

  18. 18
    top 2.3%

    Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy

    Michael Drummond, Peter J. Neumann, Sean D. Sullivan, Frank-Ulrich Fricke, Sean Tunis and 2 more

    92 citationsOpen accessdoi:10.1016/j.jval.2019.03.012OpenAlex

  19. 19
    top 2.5%

    Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?

    John Edward Brazier, Donna Rowen, Andrew J. Lloyd, Milad Karimi

    88 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2018.12.001OpenAlex

    Show abstract

    The widespread adoption of the EuroQol 5-dimensional questionnaire (EQ-5D) has been important for the comparability, transparency, and consistency of economic evaluations for informing resource allocation in healthcare. The objectives of this article were to (1) critically assess whether the widespread adoption of the EQ-5D and its time trade-off-based value sets to inform economic evaluation is likely to continue and (2) speculate about how benefits may be measured and valued to inform economic evaluation in the future. Evidence supports the use of the EQ-5D in many areas of health, but there are notable gaps. Furthermore, there has been interest among some policy makers in measuring changes in well-being, and in using common outcomes across sectors. Possibilities for measuring well-being alongside health can be achieved through bolt-on dimensions or an entirely new measure capturing both health and well-being. Nevertheless, there are significant concerns about the logic of estimating a common utility function. The development of online valuation methods has had a major impact on…

  20. 22
    top 2.9%

    Using Machine Learning Applied to Real-World Healthcare Data for Predictive Analytics: An Applied Example in Bariatric Surgery

    Stephen S. Johnston, John M. Morton, Iftekhar D. Kalsekar, Eric M. Ammann, Chia‐Wen Hsiao and 1 more

    78 citationsOpen accessdoi:10.1016/j.jval.2019.01.011OpenAlex

  21. 25
    top 3.2%

    Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America

    Nahila Justo, Manuel Espinoza, Barbara Elizabeth Ratto, Martha Nicholson, Diego Rosselli and 5 more

    73 citationsOpen accessdoi:10.1016/j.jval.2019.01.014OpenAlex

  22. 26
    top 3.4%

    Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?

    Vivian Reckers‐Droog, Job N. A. van Exel, Werner B. F. Brouwer

    63 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.07.012OpenAlex

    Show abstract

    BACKGROUND: Priority setting in healthcare can be guided by both efficiency and equity principles. The latter principle is often explicated in terms of disease severity and, for example, defined as absolute or proportional shortfall. These severity operationalizations do not explicitly consider patients' age, even though age may be inextricably related to severity and an equity-relevant characteristic. OBJECTIVE: This study examines the relative strength of societal preferences for severity and age for informing allocation decisions in healthcare. METHODS: We elicited preferences for severity and age in a representative sample of the public in The Netherlands (N = 1025) by applying choice tasks and person-trade-off tasks in a design in which severity levels and ages varied both separately and simultaneously between patient groups. We calculated person trade-off ratios and, in addition, applied ordinary least squares regression models to aid interpretation of the ratios when both severity and age varied. RESULTS: Respondents attached a higher weight (median of ratios: 2.46-3.50) to…

  23. 28
    top 3.6%

    Computing PROPr Utility Scores for PROMIS® Profile Instruments

    Barry Dewitt, Hawre J. Jalal, Janel Hanmer

    57 citationsOpen accessdoi:10.1016/j.jval.2019.09.2752OpenAlex

  24. 29
    top 3.7%

    Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs

    Kent E. Hutchison, L. Cinnamon Bidwell, Jarrod M. Ellingson, Angela D. Bryan

    55 citationsOpen accessdoi:10.1016/j.jval.2019.05.005OpenAlex

  25. 30
    top 3.9%

    Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions

    Tinevimbo Shiri, Kamran Khan, Katherine Keaney, Geetanjali Mukherjee, Noel Denis McCarthy and 1 more

    52 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.06.011OpenAlex

    Show abstract

    BACKGROUND: Pneumococcal diseases cause substantial mortality, morbidity, and economic burden. Evidence on data inputs for economic evaluations of interventions targeting pneumococcal disease is critical. OBJECTIVES: To summarize evidence on resource use, costs, health utilities, and cost-effectiveness for pneumococcal disease and associated interventions to inform future economic analyses. METHODS: We searched MEDLINE, Embase, Web of Science, CINAHL, PsycINFO, EconLit, and Cochrane databases for peer-reviewed studies in English on pneumococcal disease that reported health utilities using direct or indirect valuation methods, resource use, costs, or cost-effectiveness of intervention programs, and summarized the evidence descriptively. RESULTS: We included 383 studies: 9 reporting health utilities, 131 resource use, 160 economic costs of pneumococcal disease, 95 both resource use and costs, and 178 economic evaluations of pneumococcal intervention programs. Health state utility values ranged from 0 to 1 for both meningitis and otitis media and from 0.3 to 0.7 for both pneumonia and…

  26. 31
    top 4%

    Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies

    James Love-Koh, Richard Cookson, Nils Gutacker, Thomas Patton, Susan C. Griffin

    51 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.03.006OpenAlex

    Show abstract

    BACKGROUND: Health inequalities can be partially addressed through the range of treatments funded by health systems. Nevertheless, although health technology assessment agencies assess the overall balance of health benefits and costs, no quantitative assessment of health inequality impact is consistently undertaken. OBJECTIVES: To assess the inequality impact of technologies recommended under the NICE single technology appraisal process from 2012 to 2014 using an aggregate distributional cost-effectiveness framework. METHODS: Data on health benefits, costs, and patient populations were extracted from the NICE website. Benefits for each technology were distributed to social groups using the observed socioeconomic distribution of hospital utilization for the targeted disease. Inequality measures and estimates of cost-effectiveness were compared using the health inequality impact plane and combined using social welfare indices. RESULTS: Twenty-seven interventions were evaluated. Fourteen interventions were estimated to increase population health and reduce health inequality, 8 to…

  27. 32
    top 4.1%

    What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges

    Samare P.I. Huls, Chiara L. Whichello, Job N. A. van Exel, Carin A. Uyl‐de Groot, Esther Wilhelmina de Bekker-Grob

    49 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.04.1930OpenAlex

    Show abstract

    BACKGROUND: Integrating patient preferences in Health Technology Assessment (HTA) is argued to improve uptake, adherence, and patient satisfaction. However, how to elicit and incorporate these preferences in HTA in a systematic and scientifically valid manner is subject to debate. OBJECTIVE: This article provides a systematic review of the challenges to integrating patient preferences in HTA that have been raised in the literature about patient preferences in HTA. METHODS: A systematic review of articles published between 2013 and 2017 addressing challenges to the integration of patient preferences in HTA was conducted in 7 databases. All issues with respect to the integration of patient preferences in HTA were extracted and divided into 5 categories: conceptual, normative, procedural, methodological, and practical issues. The issues were ranked according to how often they were mentioned. RESULTS: Of 2147 retrieved articles, 67 were included in the analysis. Thirty-seven unique research issues were identified. In the majority of the articles, methodological issues were posed (82%),…

  28. 33
    top 4.3%

    R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment

    Devin Incerti, Howard H. Z. Thom, Gianluca Baio, Jeroen Paul Jansen

    49 citationsOpen accessdoi:10.1016/j.jval.2019.01.003OpenAlex

  29. 35
    top 4.5%

    Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis

    Stacie A. Hudgens, René Schüler, Jonathan Stokes, Sonya L. Eremenco, Elke Hunsche and 1 more

    47 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2018.11.007OpenAlex

    Show abstract

    OBJECTIVES: A new patient-reported outcome (PRO) instrument to measure fatigue symptoms and impacts in relapsing multiple sclerosis (RMS) was developed in a qualitative stage, followed by psychometric validation and migration from paper to an electronic format. METHODS: Adult patients with relapsing-remitting multiple sclerosis (RRMS) were interviewed to elicit fatigue-related symptoms and impacts. A draft questionnaire was debriefed in cognitive interviews with further RRMS patients, and revised. Content confirmation interviews were conducted with patients with progressive-relapsing multiple sclerosis (PRMS) and relapsing secondary-progressive multiple sclerosis (RSPMS). Psychometric analyses used data from adult patients with different RMS subtypes and matched non-RMS controls in a multicenter, observational study. After item reduction, the final instrument was migrated to a smartphone (eDiary) and usability was confirmed in interviews with additional adult RMS patients. RESULTS: The qualitative stage included 37 RRMS, 5 PRMS, and 5 RSPMS patients. Saturation of concepts was…

  30. 36
    top 4.6%

    A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C

    Yasmin A. Saeed, Arcturus Phoon, JOANNA M. BIELECKI, Nicholas Mitsakakis, Karen E. Bremner and 5 more

    45 citationsOpen accessdoi:10.1016/j.jval.2019.07.005OpenAlex

  31. 39
    top 5%
  32. 40
    top 5.2%

    Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2

    Thomas G. Poder, Vickie Fauteux, Jie He Ψ, John Edward Brazier

    41 citationsOpen accessdoi:10.1016/j.jval.2018.12.012OpenAlex

  33. 41
    top 5.3%

    Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review

    Claire Gorry, Laura McCullagh, Michael G. Barry

    40 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.07.003OpenAlex

    Show abstract

    BACKGROUND: Many high cost treatments for advanced melanoma have become available in recent years. National health technology assessment agencies have raised concerns regarding uncertainty in their clinical and cost-effectiveness. OBJECTIVE: The aim of this systematic review is to identify economic evaluations of treatments for advanced melanoma and review model assumptions, outcomes, and quality as preparation for a health technology assessment. METHODS: A search of Embase, MEDLINE, EconLit, and the Cochrane Database was conducted. Only studies using decision-analytic models were included. Two authors independently completed full-text review and data extraction. RESULTS: Fifteen studies were identified. There were major differences in the structural assumptions underpinning the models. There was general agreement in study conclusions, although the predicted costs and quality-adjusted life years for each treatment varied. BRAF monotherapy (vemurafenib, dabrafenib) or BRAF/MEK combination therapy (BRAF monotherapy with cobimetinib or trametinib) has not been shown to be…

  34. 42
    top 5.4%

    Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

    Bhavani Shankara Bagepally, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Usa Chaikledkaew and 1 more

    39 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.09.2750OpenAlex

    Show abstract

    Objectives Type 2 diabetes mellitus (T2DM) and associated ailments are leading economic burdens to society. Sodium glucose cotransporter-2 (SGLT2) inhibitors are recent antidiabetic medications with beneficial clinical efficacy. This meta-analysis was conducted to quantitatively pool the incremental net benefit of SGLT2 inhibitors in T2DM patients who failed metformin monotherapy. Methods Relevant economic evaluation studies of T2DM patients were identified from PubMed, Scopus, ProQuest, the Cochrane Library, and the Tufts Cost-Effective Analysis Registry until June 2018. Studies were eligible if they studied T2DM patients who failed metformin monotherapy and assessed the cost-effectiveness/utility between SGLT2 inhibitors and other treatments. Details of the study characteristics, economic model inputs, costs, and outcomes were extracted. Risk of bias was assessed using the biases in economic studies (ECOBIAS) checklist. The incremental net benefit was calculated with monetary units adjusting for purchasing power parity for 2017 US dollars. This was then pooled across studies…

  35. 43
    top 5.5%
  36. 44
    top 5.7%

    Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

    Olivia M Dong, Stephanie B. Wheeler, Gracelyn Cruden, Craig R. Lee, Deepak Voora and 2 more

    38 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.08.002OpenAlex

    Show abstract

    OBJECTIVE: To evaluate the cost-effectiveness of multigene testing (CYP2C19, SLCO1B1, CYP2C9, VKORC1) compared with single-gene testing (CYP2C19) and standard of care (no genotyping) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) from Medicare's perspective. METHODS: A hybrid decision tree/Markov model was developed to simulate patients post-PCI for ACS requiring antiplatelet therapy (CYP2C19 to guide antiplatelet selection), statin therapy (SLCO1B1 to guide statin selection), and anticoagulant therapy in those that develop atrial fibrillation (CYP2C9/VKORC1 to guide warfarin dose) over 12 months, 24 months, and lifetime. The primary outcome was cost (2016 US dollar) per quality-adjusted life years (QALYs) gained. Costs and QALYs were discounted at 3% per year. Probabilistic sensitivity analysis (PSA) varied input parameters (event probabilities, prescription costs, event costs, health-state utilities) to estimate changes in the cost per QALY gained. RESULTS: Base-case-discounted results indicated that the cost per QALY gained was $59…

  37. 45
    top 5.8%
  38. 47
    top 6%

    Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana

    Mohamed M Gad, Joanne L. Lord, Kalipso Chalkidou, Brian Adu Asare, Martha Gyansa‐Lutterodt and 1 more

    37 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.09.2749OpenAlex

    Show abstract

    OBJECTIVES: Universal healthcare coverage in low- and middle-income countries requires challenging resource allocation decisions. Health technology assessment is one important tool to support such decision making. The International Decision Support Initiative worked with the Ghanaian Ministry of Health to strengthen health technology assessment capacity building, identifying hypertension as a priority topic area for a relevant case study. METHODS: Based on guidance from a national technical working group of researchers and policy makers, an economic evaluation and budget impact analysis were undertaken for the main antihypertensive medicines used for uncomplicated, essential hypertension. The analysis aimed to address specific policy questions relevant to the National Health Insurance Scheme. RESULTS: The evaluation found that first-line management of essential hypertension with diuretics has an incremental cost per disability-adjusted life-year avoided of GH¢ 276 ($179 in 2017, 4% of gross national income per capita) compared with no treatment. Calcium channel blockers were more…

  39. 48
    top 6.2%

    Optimal Design of Population-Level Financial Incentives of Influenza Vaccination for the Elderly

    Mu Yue, Yi Wang, Chng Kiat Low, Joanne Yoong, Alex Richard Cook

    37 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.08.006OpenAlex

    Show abstract

    OBJECTIVES: To identify how monetary incentives affect influenza vaccination uptake rate using a randomized control experiment and to subsequently design an optimal incentive program in Singapore, a high-income country with a market-based healthcare system. METHODS: 4000 people aged ≥65 were randomly assigned to 4 treatment groups (1000 each) and were offered a monetary incentive (in shopping vouchers) if they chose to participate. The baseline group was invited to complete a questionnaire with incentives of 10 Singapore dollars (SGD; where 1 SGD ≈ 0.73 USD), whereas the other three groups were invited to complete the questionnaire and be vaccinated against influenza at their own cost of around 32 SGD, in return for incentives of 10, 20, or 30 SGD. RESULTS: Increasing the total incentive for vaccination and reporting from 10 to 20 SGD increased participation in vaccination from 4.5% to 7.5% (P < .001). Increasing the total incentive from 20 to 30 SGD increased the participation rate to 9.2%, but this was not statistically significantly different from a 20-SGD incentive. The group of…

  40. 49
    top 6.3%

    A Comparison of National Guidelines for Network Meta-Analysis

    A Laws, Ran Tao, Sisi Wang, Amie Padhiar, Sarah M. Goring

    37 citationsOpen accessdoi:10.1016/j.jval.2019.05.013OpenAlex

  41. 50
    top 6.4%

    A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis

    Laura Flight, Fahid Arshad, Rachel Barnsley, Kian Patel, Steven A. Julious and 2 more

    37 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2018.11.008OpenAlex

    Show abstract

    OBJECTIVE: An adaptive design uses data collected as a clinical trial progresses to inform modifications to the trial. Hence, adaptive designs and health economics aim to facilitate efficient and accurate decision making. Nevertheless, it is unclear whether the methods are considered together in the design, analysis, and reporting of trials. This review aims to establish how health economic outcomes are used in the design, analysis, and reporting of adaptive designs. METHODS: Registered and published trials up to August 2016 with an adaptive design and health economic analysis were identified. The use of health economics in the design, analysis, and reporting was assessed. Summary statistics are presented and recommendations formed based on the research team's experiences and a practical interpretation of the results. RESULTS: Thirty-seven trials with an adaptive design and health economic analysis were identified. It was not clear whether the health economic analysis accounted for the adaptive design in 17/37 trials where this was thought necessary, nor whether health economic…

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to Value in Health with publication year 2019, excluding retracted works and paratext such as editorials and errata. The top 50 by citation count are listed; the percentile is the rank divided by the cohort size. 20 of the 50 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 25 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.